Full-Scenario Ecosystem, Measured Outcomes: Haier Biomedical Suzhou Builds Pharmacy Automation Brand Moat

Established in 2015 as the core intelligent pharmacy unit under Haier Biomedical, operating a 13,000m² facility with 500 employees including 100 R&D engineers.

CALIFORNIA, CA, UNITED STATES, October 22, 2026 /EINPresswire.com/ -- SUZHOU, China — Haier Biomedical Technology (Suzhou) Co., Ltd., the hospital pharmacy automation business of Haier Biomedical, holds European Union verifications of conformity covering automated dispensing systems, high-speed dispensing systems and anaesthetic medication cabinets, according to certificates issued by the conformity assessment body ICR. The company, founded in 2015, operates a 13,000 m² manufacturing and research facility in Suzhou with 500 employees, including 100 engineers, and supplies outpatient automated dispensing systems, inpatient pharmacy automation systems, automated PIVAS systems and a fully automated cytotoxic drug compounding robot.

The certificates were issued between April 2025 and August 2025 and remain valid into 2029 and 2030. Each names the specific equipment models covered, a detail that matters to hospital procurement teams assessing whether a certified configuration matches the model they intend to install.


The demand base: hospital pharmacies and IV compounding

Pharmacy automation spending is concentrated in hospital settings. Fortune Business Insights identified hospital pharmacies as the largest segment of the pharmacy automation market in 2024, citing high patient volumes and complex medication regimens. Insightace Analytic estimated the global pharmacy automation devices market at USD 6.7 billion in 2024, while Grand View Research projects the market to reach USD 11.6 billion by 2030, equivalent to a compound annual growth rate of 9.9%.

Product-level data points to two centres of gravity. Dataintelo estimated that medication dispensing systems held the largest product segment share at 32.5% in 2025. Grand View Research projects automated medication compounding to be the fastest-growing segment, with a CAGR above 10%. Grand View Research separately estimates that the China pharmacy automation market will grow at a 5.6% CAGR between 2025 and 2030.

At group level, Haier Biomedical reported total revenue of RMB 2.33 billion (approximately USD 340.77 million) in 2025, with overseas revenue of RMB 840 million, up 17.9% year on year, according to the company annual report distributed via PR Newswire.


Scope of the Suzhou portfolio

The Suzhou unit's product architecture covers outpatient dispensing, inpatient pharmacy storage and dispensing, automated PIVAS and high-risk drug handling. Company documentation lists outpatient automated dispensing systems, inpatient pharmacy automation systems, automated PIVAS systems and a cytotoxic drug compounding robot as its four main product families, supported by dispensing cabinets and a sub-packaging and verification machine. Published specifications for the principal platforms include:

Robotic Arm Dispenser HOH-KF-Smart — at least 1,500 medication types and storage for at least 20,000 boxes, with dispensing speed of at least 300 prescriptions per hour and replenishment of at least 700 boxes per hour; FIFO/FEFO expiry management and barcode-based traceability across the medication chain.

Chute Type Dispenser HOH-KF-1200 — more than 1,100 medication types and more than 15,000 boxes of storage within a footprint under 12.85 m²; 350 to 500 prescriptions per hour, replenishment above 2,400 boxes per hour, at least two dispensing buffer channels and parallel multi-prescription operation.
High Speed Dispenser HOH-GF (two modules) — at least 100 storage slots, capacity for at least 5,000 boxes and single-channel dispensing of at least two boxes per second, with photoelectric sensors for dispensing detection and indicator-light error guidance.

Automatic Sub-packaging and Verification Machine HOH-FB-D400-HD — 400 medication boxes, packaging speed of 40 to 60 packs per minute and a 72-slot external output tray.

Intelligent Integrated Management Cabinet HOH-BQ-A and Anesthetic Medication Dispensing Cabinet HOH-MJ-01 — 23-inch touchscreen control on the HOH-BQ-A; nine drawers and 44 compartments on the HOH-MJ-01.

Hospitals integrating these units run them against existing hospital information systems. Company documentation states that the solutions support integration with HIS and EMR platforms, with prescription information transferred to the automation layer and processed according to configured dispensing rules.


PIVAS and cytotoxic drug compounding

The Fully Automated Cytotoxic Drug Compounding Robot HOH-Robot-Plus measures 2,200 × 1,520 × 2,370 mm and weighs 1,300 kg. The company lists compatibility with more than 95% of vial types, a compounding rate of 25 preparations per hour and support for solvent containers from 50 mL to 1,000 mL, including soft bags, plastic bottles and stand-up pouches. Compounding takes place under Class 100 (ISO 5) cleanroom conditions, and the company lists compounding accuracy of 100%.

Automated compounding is the segment third-party analysts expect to expand fastest, which places hazardous-drug preparation alongside dispensing as a category where configuration depth and certification scope are examined during evaluation rather than after installation.


Certification and quality management

The EU verifications of conformity issued to the Suzhou unit specify both the models covered and the safety standards applied. The published certificates list the following scopes:

ICR/VC/HB250402, issued 17 April 2025 and valid to 16 April 2030, covering automatic dispensing system models HOH-KF-1200, HOH-KF-900, HOH-KF-600, HOH-KF-Smart, HOH-KF-ADM, HOH-KF-50, HOH-KF-40 and HOH-KF-30Z, assessed against EN ISO 12100:2010 and EN 60204-1:2018.

ICR/VC/HB250403, issued 17 April 2025 and valid to 16 April 2030, covering high-speed dispensing system models HOH-GF-36, HOH-GF-50, HOH-GF-72, HOH-GF-100, HOH-GF-144 and HOH-GF-200.

ICR/VC/HB240501, issued 10 May 2025 and valid to 9 May 2029, covering anaesthetic medication dispensing cabinet models including HOH-MJ-01, HOH-BQ-A and HOH-M600-A.

ICR/VC/HB250802, issued 6 August 2025 and valid to 5 August 2030, covering sub-packaging and inspection machine models HOH-FB-D400-HD, HOH-FB-D320-HD and HOH-FB-D480-HD.

ISETC.000220220323, an ISET voluntary compliance certificate issued 23 March 2022 and valid to 22 March 2027, covering automatic dispensing system models including HOH-KF-Smart and HOH-KF-ADM.

The company also holds ISO 9001 and ISO 13485 medical device quality management system certification and CE marking. External references describe the regulatory baseline for this equipment class: CSA Group notes that pharmacy automation systems must comply with IEC 60601-1 for medical electrical equipment safety and ISO 13485 for quality management, while the U.S. Food and Drug Administration's 21 CFR Part 11 governs electronic records and electronic signatures where such records are used.


Southeast Asian deployments cited by the company

Two hospital installations in Southeast Asia are documented in the company's case records. In Thailand, a private hospital took delivery of one set of a
customized universal dispenser system configured for local medication packaging formats. The company states that the configuration supports HIS integration and a modular design intended to accommodate later expansion.

In Vietnam, a general hospital installed one set of an intelligent pharmacy automation system covering automated storage, dispensing and medication management in the outpatient pharmacy. The company reports that the project reduced patient waiting time and optimized dispensing workflows, and that customer feedback indicated stable dispensing with improved accuracy and fewer repetitive tasks for pharmacy staff.

Both accounts are company-reported and do not include independently audited performance data. They remain the clearest public evidence of the unit's deployment record outside China, alongside the company's statement that its solutions are in use in hospitals across Asia and other international markets.


Manufacturing terms: OEM, ODM and a one-unit minimum order

Production is organized on a project basis. The company offers OEM, ODM and full customization across equipment size, storage capacity, SKU quantity, robotic modules, software functions, HIS interface and language. Minimum order quantity is one unit, and lead time is typically 60 to 90 days depending on project size and configuration.

Quality control includes a Factory Acceptance Test before shipment. Post-delivery services listed by the company comprise remote technical support, on-site installation and commissioning, operator training, software upgrades, spare parts supply and global after-sales service. Export markets listed are Europe, the Middle East, Southeast Asia, Latin America, Africa and Oceania.


How hospital buyers evaluate suppliers in this segment

Procurement teams evaluating pharmacy automation typically compare suppliers against a set of operational questions rather than a single specification. The criteria below correspond to the points the Suzhou unit's documentation addresses.

Scenario coverage — whether outpatient dispensing, inpatient storage, IV compounding and hazardous-drug handling can be sourced and integrated within one supplier scope.

System integration — whether the automation layer exchanges prescription data with HIS and EMR platforms, and whether interface work falls inside the customization scope.

Throughput against prescription volume — dispensing rates per hour, replenishment rates and buffer capacity, matched to peak outpatient load.

Traceability and expiry control — FIFO/FEFO management and barcode-based monitoring from storage to the dispensing point.

Certification scope — whether the specific model under consideration appears on the certificate, and which safety standards were applied.

Deployment model — one-unit minimum orders, customization of capacity and software, and factory acceptance testing before shipment.

The competitive field is established. Dataintelo identifies BD and Omnicell as leading competitors in the global pharmacy automation landscape. The Suzhou unit's stated position rests on combined coverage of dispensing and IV preparation, configuration flexibility down to single-unit orders, and a certification footprint that lists models individually rather than by product family.


Market impact

For hospital groups and distributors assessing supplier depth, three elements of the Suzhou unit's profile are relevant. The first is scope: a supplier able to deliver dispensing, inpatient automation and IV compounding reduces the number of integration boundaries a hospital must manage. The second is manufacturing flexibility: a one-unit minimum order and 60-to-90-day lead times make staged pharmacy upgrades feasible for individual sites. The third is documentation: model-level EU verifications allow a buyer to match a certificate to the exact configuration under consideration.

MarketsandMarkets projects pharmacy automation software to grow at the fastest rate among components from 2024 to 2030, which places weight on interface capability as well as hardware throughput. Software functions, HIS interfaces and language adaptation are listed within the customization scope offered by the Suzhou unit.


Outlook

With the global market projected at USD 11.6 billion by 2030 and automated compounding growing above 10% annually, the evaluation criteria applied by
hospital buyers are converging on scope, traceability and documentation rather than on equipment alone. For Haier Biomedical Technology (Suzhou) Co., Ltd., the certificates valid into 2029 and 2030 set the near-term compliance baseline, while the deployments recorded in Thailand and Vietnam provide reference points for buyers in the same regions.

Gina
Haier Biomedical Technology（Suzhou）Co., Ltd
+ +86-187 7008 3375
smartpharmacy@haierbiomedical.com
Visit us on social media:
Other